$SBRA
Sabra Health Care REIT, Inc. Stock $sbra

$sbra Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149229824000025 Filed on August 07, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$178.0M	$176.1M
YoY Change	10.13%	9.29%
Cost Of Revenue	$54.23M	$50.36M
YoY Change	21.81%	14.54%
Gross Profit	$123.8M	$125.8M
YoY Change	5.69%	7.32%
Gross Profit Margin	69.53%	71.41%
Selling, General & Admin	$12.26M	$12.58M
YoY Change	10.54%	26.29%
% of Gross Profit	9.9%	10.0%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$42.72M	$41.68M
YoY Change	-1.21%	-5.58%
% of Gross Profit	34.52%	33.14%
Operating Expenses	$59.25M	$58.66M
YoY Change	1.05%	-0.37%
Operating Profit	$64.52M	$67.13M
YoY Change	10.35%	15.09%
Interest Expense	-$29.25M	-$29.23M
YoY Change	1.57%	0.87%
% of Operating Profit	-45.34%	-43.55%
Other Income/Expense, Net	-$5.745M	$1.854M
YoY Change	-87.04%	-123.67%
Pretax Income	$29.31M	$24.33M
YoY Change	-309.34%	9.77%
Income Tax	-$265.0K	$437.0K
% Of Pretax Income	-0.9%	1.8%
Net Earnings	$29.79M	$23.98M
YoY Change	-297.26%	13.15%
Net Earnings / Revenue	16.73%	13.61%
Basic Earnings Per Share	$0.13	$0.10
Diluted Earnings Per Share	$0.13	$0.10
COMMON SHARES
Basic Shares Outstanding	234.3M shares	231.5M shares
Diluted Shares Outstanding	237.0M shares	233.8M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$63.00M	$36.40M
YoY Change	89.45%	33.65%
Cash & Equivalents	$63.00M	$36.40M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$177.3M	$171.8M
YoY Change	-4.44%	-1.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.581B	$4.577B
YoY Change	-0.47%	-3.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$130.8M	$129.8M
YoY Change	-3.64%	-7.57%
Other Assets	$5.972M	$5.911M
YoY Change	6.6%	14.87%
Total Long-Term Assets	$5.189B	$5.179B
YoY Change	-0.12%	-3.2%
TOTAL ASSETS
Total Short-Term Assets	$177.3M	$171.8M
Total Long-Term Assets	$5.189B	$5.179B
Total Assets	$5.366B	$5.351B
YoY Change	-0.27%	-3.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$91.11M	$83.23M
YoY Change	-14.81%	-21.08%
Accrued Expenses	$31.70M	$29.60M
YoY Change	50.24%	80.49%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$122.8M	$112.8M
YoY Change	-4.09%	-7.41%
LONG-TERM LIABILITIES
Long-Term Debt	$2.470B	$2.447B
YoY Change	5.14%	1.1%
Other Long-Term Liabilities	$28.27M	$29.69M
YoY Change	-17.32%	-23.24%
Total Long-Term Liabilities	$2.498B	$2.476B
YoY Change	4.82%	0.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$122.8M	$112.8M
Total Long-Term Liabilities	$2.498B	$2.476B
Total Liabilities	$2.621B	$2.589B
YoY Change	4.36%	0.33%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock	$2.366M	$2.343M
YoY Change	2.34%	1.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.745B	$2.762B
YoY Change
Total Liabilities & Shareholders Equity	$5.366B	$5.351B
YoY Change	-0.27%	-3.14%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	$29.79M	$23.98M
YoY Change	-297.26%	13.15%
Depreciation, Depletion And Amortization	$42.72M	$41.68M
YoY Change	-1.21%	-5.58%
Cash From Operating Activities	$97.65M	$80.13M
YoY Change	17.35%	13.93%
INVESTING ACTIVITIES
Capital Expenditures	$76.10M	$36.13M
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$19.07M	-$21.18M
YoY Change	-68.18%	158.5%
Cash From Investing Activities	-$57.03M	-$57.31M
YoY Change	-195.17%	599.46%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-13.95M	-46.41M
YoY Change	-89.77%	-32.22%
NET CHANGE
Cash From Operating Activities	97.65M	80.13M
Cash From Investing Activities	-57.03M	-57.31M
Cash From Financing Activities	-13.95M	-46.41M
Net Change In Cash	26.67M	-23.59M
YoY Change	295.04%	272.29%
FREE CASH FLOW
Cash From Operating Activities	$97.65M	$80.13M
Capital Expenditures	$76.10M	$36.13M
Free Cash Flow	$21.55M	$44.00M
YoY Change	-74.1%	-37.44%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	231266020	shares
CY2022Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	6611000	usd
CY2024Q1	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.30
CY2024Q2	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.30
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1400000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	21188000	usd
	us-gaap	Net Income Loss NetIncomeLoss	50229000	usd
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	231536286	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	231184355	shares
CY2023Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1040057	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2047585	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1030088	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	232244588	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	233583871	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	232214443	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.22
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.22
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	234262497	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	234262497	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	231266020	shares
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4250000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-20944000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-160000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-608000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	46719000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53932000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	42309000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32380000	usd
	us-gaap	Interest Paid Net InterestPaidNet	50847000	usd
	us-gaap	Interest Paid Net InterestPaidNet	52591000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	0	usd
	us-gaap	Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1 NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1	4644000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.sabrahealth.com/20240630#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://www.sabrahealth.com/20240630#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2024Q2	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
CY2023Q4	us-gaap	Operating Lease Liability Statement Of Financial Position Extensible List OperatingLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent
CY2024Q2	us-gaap	Derivative Asset Statement Of Financial Position Extensible Enumeration DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration	http://www.sabrahealth.com/20240630#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2023Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2024#LineOfCredit http://fasb.org/us-gaap/2024#LoansPayableToBank
CY2023Q4	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2024#AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent http://fasb.org/us-gaap/2024#LineOfCredit http://fasb.org/us-gaap/2024#LoansPayableToBank
CY2024Q2	us-gaap	Derivative Asset Statement Of Financial Position Extensible Enumeration DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration	http://www.sabrahealth.com/20240630#AccountsReceivablePrepaidExpensesDeferredFinancingCostsAndOtherAssetsNet
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8706000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6277000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-20984000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-8019000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	132923000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	138618000	usd
	us-gaap	Payments To Acquire Real Estate PaymentsToAcquireRealEstate	36128000	usd
	us-gaap	Payments To Acquire Real Estate PaymentsToAcquireRealEstate	39630000	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	19752000	usd
	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	9050000	usd
	sbra	Payments For Preferred Equity Investments PaymentsForPreferredEquityInvestments	1021000	usd
	sbra	Payments For Preferred Equity Investments PaymentsForPreferredEquityInvestments	10676000	usd
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	25360000	usd
	us-gaap	Payments To Acquire Furniture And Fixtures PaymentsToAcquireFurnitureAndFixtures	37995000	usd
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	1189000	usd
	us-gaap	Proceeds From Collection Of Notes Receivable ProceedsFromCollectionOfNotesReceivable	8062000	usd
	sbra	Repayments Of Preferred Equity Investments RepaymentsOfPreferredEquityInvestments	-4727000	usd
	sbra	Repayments Of Preferred Equity Investments RepaymentsOfPreferredEquityInvestments	-4130000	usd
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	344000	usd
	us-gaap	Payments To Acquire Interest In Joint Venture PaymentsToAcquireInterestInJointVenture	4797000	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	6158000	usd
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	168904000	usd
	us-gaap	Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity	0	usd
	us-gaap	Proceeds From Lease Payment Sales Type And Direct Financing Leases Investing Activity ProceedsFromLeasePaymentSalesTypeAndDirectFinancingLeasesInvestingActivity	25490000	usd
	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	0	usd
	us-gaap	Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital	544000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-70531000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	104982000	usd
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	36939000	usd
	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-98857000	usd
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	0	usd
	us-gaap	Proceeds From Issuance Of Medium Term Notes ProceedsFromIssuanceOfMediumTermNotes	12188000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	1010000	usd
	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	983000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	80000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	18128000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	17900000	usd
	sbra	Proceeds Payments From Issuance Of Stock Net Of Taxes Paid On Behalf Of Employees ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees	36403000	usd
	sbra	Proceeds Payments From Issuance Of Stock Net Of Taxes Paid On Behalf Of Employees ProceedsPaymentsFromIssuanceOfStockNetOfTaxesPaidOnBehalfOfEmployees	-2153000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	138894000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	138711000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-66642000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-264544000	usd
CY2024Q2	sbra	Real Estate Investments Joint Ventures Number RealEstateInvestmentsJointVenturesNumber	0	investment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.</span></div>
CY2024Q2	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	5658740000	usd
CY2024Q2	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	1092581000	usd
CY2024Q2	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	4566159000	usd
CY2023Q4	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	5638347000	usd
CY2023Q4	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	1021086000	usd
CY2023Q4	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	4617261000	usd
CY2024Q2	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	4864328000	usd
CY2023Q4	us-gaap	Buildings And Improvements Gross BuildingsAndImprovementsGross	4843258000	usd
CY2024Q2	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	239384000	usd
CY2023Q4	us-gaap	Fixtures And Equipment Gross FixturesAndEquipmentGross	238185000	usd
CY2024Q2	us-gaap	Land Improvements LandImprovements	10812000	usd
CY2023Q4	us-gaap	Land Improvements LandImprovements	10306000	usd
CY2024Q2	us-gaap	Land Land	544216000	usd
CY2023Q4	us-gaap	Land Land	546598000	usd
CY2024Q2	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	5658740000	usd
CY2023Q4	us-gaap	Real Estate Investment Property At Cost RealEstateInvestmentPropertyAtCost	5638347000	usd
CY2024Q2	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	1092581000	usd
CY2023Q4	us-gaap	Real Estate Investment Property Accumulated Depreciation RealEstateInvestmentPropertyAccumulatedDepreciation	1021086000	usd
CY2024Q2	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	4566159000	usd
CY2023Q4	us-gaap	Real Estate Investment Property Net RealEstateInvestmentPropertyNet	4617261000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	17000000	usd
CY2024Q2	us-gaap	Equity Method Investments EquityMethodInvestments	129773000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	136843000	usd
	sbra	Disposal Group Including Discontinued Operations Number Of Properties DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties	4	facility
	sbra	Disposal Group Including Discontinued Operations Number Of Properties DisposalGroupIncludingDiscontinuedOperationsNumberOfProperties	12	facility
CY2024Q2	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	6200000	usd
CY2023Q2	us-gaap	Disposal Group Including Discontinued Operation Consideration DisposalGroupIncludingDiscontinuedOperationConsideration	176900000	usd
CY2024Q2	sbra	Disposal Group Including Discontinued Operation Assets And Liabilities Net DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet	4400000	usd
CY2023Q2	sbra	Disposal Group Including Discontinued Operation Assets And Liabilities Net DisposalGroupIncludingDiscontinuedOperationAssetsAndLiabilitiesNet	206300000	usd
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	1800000	usd
	us-gaap	Disposal Group Not Discontinued Operation Gain Loss On Disposal DisposalGroupNotDiscontinuedOperationGainLossOnDisposal	-29400000	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-1100000	usd
	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-37400000	usd
	us-gaap	Disposal Group Not Discontinued Operation Loss Gain On Write Down DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown	3100000	usd
	us-gaap	Disposal Group Not Discontinued Operation Loss Gain On Write Down DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown	7100000	usd
CY2024Q2	us-gaap	Security Deposit Liability SecurityDepositLiability	8500000	usd
CY2023Q4	us-gaap	Security Deposit Liability SecurityDepositLiability	16400000	usd
CY2024Q2	sbra	Letters Of Credit Deposits LettersOfCreditDeposits	65000000	usd
CY2023Q4	sbra	Letters Of Credit Deposits LettersOfCreditDeposits	56000000	usd
CY2024Q2	sbra	Property Taxes Insurance And Tenant Improvement Deposit Liability PropertyTaxesInsuranceAndTenantImprovementDepositLiability	12300000	usd
CY2023Q4	sbra	Property Taxes Insurance And Tenant Improvement Deposit Liability PropertyTaxesInsuranceAndTenantImprovementDepositLiability	12400000	usd
CY2024Q2	us-gaap	Variable Lease Income VariableLeaseIncome	3200000	usd
	us-gaap	Variable Lease Income VariableLeaseIncome	6500000	usd
CY2023Q2	us-gaap	Variable Lease Income VariableLeaseIncome	3800000	usd
	us-gaap	Variable Lease Income VariableLeaseIncome	7600000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear	186733000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Next Twelve Months LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths	371459000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Two Years LessorOperatingLeasePaymentsToBeReceivedTwoYears	355491000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Three Years LessorOperatingLeasePaymentsToBeReceivedThreeYears	335059000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received Four Years LessorOperatingLeasePaymentsToBeReceivedFourYears	312759000	usd
CY2024Q2	sbra	Lessor Operating Lease Payment To Be Received After Year Four LessorOperatingLeasePaymentToBeReceivedAfterYearFour	1377855000	usd
CY2024Q2	us-gaap	Lessor Operating Lease Payments To Be Received LessorOperatingLeasePaymentsToBeReceived	2939356000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10700000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	11600000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	12400000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	12500000	usd
CY2024Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	800000	usd
CY2023Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P17Y
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	680000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1802000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1324000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1347000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1330000	usd
CY2024Q2	sbra	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	18104000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	24587000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12232000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	12355000	usd
CY2024Q2	sbra	Financing Receivable Number Of Loans FinancingReceivableNumberOfLoans	14	loan
CY2024Q2	sbra	Financing Receivable Principal Amount FinancingReceivablePrincipalAmount	391490000	usd
CY2024Q2	us-gaap	Notes Receivable Gross NotesReceivableGross	388053000	usd
CY2023Q4	us-gaap	Notes Receivable Gross NotesReceivableGross	369440000	usd
CY2024Q2	sbra	Financing Receivable Fixed Interest Rate FinancingReceivableFixedInterestRate	0.078
CY2024Q2	sbra	Financing Receivable Effective Interest Rate FinancingReceivableEffectiveInterestRate	0.077
CY2024Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	6367000	usd
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	6665000	usd
CY2024Q2	sbra	Financing Receivable Principal Amount FinancingReceivablePrincipalAmount	391490000	usd
CY2024Q2	us-gaap	Notes Receivable Net NotesReceivableNet	381686000	usd
CY2023Q4	us-gaap	Notes Receivable Net NotesReceivableNet	362775000	usd
CY2024Q2	sbra	Preferred Equity Investments Number PreferredEquityInvestmentsNumber	5	preferredequityinvestment
CY2024Q2	sbra	Preferred Equity Investment Face Value PreferredEquityInvestmentFaceValue	57141000	usd
CY2024Q2	sbra	Preferred Equity Investment Carrying Amount PreferredEquityInvestmentCarryingAmount	57329000	usd
CY2023Q4	sbra	Preferred Equity Investment Carrying Amount PreferredEquityInvestmentCarryingAmount	57849000	usd
CY2024Q2	sbra	Preferred Equity Investment Weighted Average Contractual Rate PreferredEquityInvestmentWeightedAverageContractualRate	0.108
CY2024Q2	sbra	Preferred Equity Investment Weighted Average Effective Rate PreferredEquityInvestmentWeightedAverageEffectiveRate	0.108
CY2024Q2	sbra	Number Of Investments NumberOfInvestments	19	investment
CY2024Q2	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	448631000	usd
CY2024Q2	sbra	Financing Receivable And Other Investments Net FinancingReceivableAndOtherInvestmentsNet	439015000	usd
CY2023Q4	sbra	Financing Receivable And Other Investments Net FinancingReceivableAndOtherInvestmentsNet	420624000	usd
CY2024Q2	sbra	Investments Weighted Average Contractual Rate InvestmentsWeightedAverageContractualRate	0.081
CY2024Q2	sbra	Investments Weighted Average Effective Rate InvestmentsWeightedAverageEffectiveRate	0.081
CY2023Q4	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	6665000	usd
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-298000	usd
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	221000	usd
CY2024Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	6367000	usd
CY2023Q2	us-gaap	Financing Receivable Allowance For Credit Losses FinancingReceivableAllowanceForCreditLosses	6832000	usd
CY2024Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	29300000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	57700000	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	28300000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	56900000	usd
CY2024Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3100000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	6100000	usd
CY2023Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3100000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	6100000	usd
CY2024Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	17200000	usd
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	16500000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	1024000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	2089000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	502147000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	232573000	usd
CY2024Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	541931000	usd
CY2024Q2	sbra	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	1187402000	usd
CY2024Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2467166000	usd
CY2024Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	4633000	usd
CY2024Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	15917000	usd
CY2024Q2	us-gaap	Long Term Debt LongTermDebt	2446616000	usd
CY2024Q2	sbra	Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax	4589000	usd
CY2023Q2	sbra	Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax	10746000	usd
	sbra	Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax	18923000	usd
	sbra	Other Comprehensive Income Loss Cash Flow And Net Investment Hedge Gain Loss Before Reclassification And Tax OtherComprehensiveIncomeLossCashFlowAndNetInvestmentHedgeGainLossBeforeReclassificationAndTax	11110000	usd
CY2024Q2	us-gaap	Derivative Fair Value Of Derivative Asset DerivativeFairValueOfDerivativeAsset	26478000	usd
CY2024Q2	us-gaap	Derivative Asset Fair Value Gross Liability DerivativeAssetFairValueGrossLiability	0	usd
CY2024Q2	us-gaap	Derivative Assets DerivativeAssets	26478000	usd
CY2024Q2	us-gaap	Derivative Collateral Obligation To Return Securities DerivativeCollateralObligationToReturnSecurities	0	usd
CY2024Q2	us-gaap	Derivative Collateral Obligation To Return Cash DerivativeCollateralObligationToReturnCash	0	usd
CY2024Q2	us-gaap	Derivative Fair Value Of Derivative Asset Amount Offset Against Collateral DerivativeFairValueOfDerivativeAssetAmountOffsetAgainstCollateral	26478000	usd
CY2024Q2	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	0	usd
CY2024Q2	us-gaap	Derivative Liability Fair Value Gross Asset DerivativeLiabilityFairValueGrossAsset	0	usd
CY2024Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	0	usd
CY2024Q2	us-gaap	Derivative Collateral Right To Reclaim Securities DerivativeCollateralRightToReclaimSecurities	0	usd
CY2024Q2	us-gaap	Derivative Collateral Right To Reclaim Cash DerivativeCollateralRightToReclaimCash	0	usd
CY2024Q2	us-gaap	Derivative Fair Value Of Derivative Liability Amount Offset Against Collateral DerivativeFairValueOfDerivativeLiabilityAmountOffsetAgainstCollateral	0	usd
CY2024Q2	sbra	Financing Receivable Principal Amount FinancingReceivablePrincipalAmount	391490000	usd
CY2023Q4	sbra	Financing Receivable Principal Amount FinancingReceivablePrincipalAmount	372873000	usd
CY2024Q2	sbra	Preferred Equity Investment Face Value PreferredEquityInvestmentFaceValue	57141000	usd
CY2023Q4	sbra	Preferred Equity Investment Face Value PreferredEquityInvestmentFaceValue	57681000	usd
CY2024Q2	us-gaap	Loans Receivable Fair Value Disclosure LoansReceivableFairValueDisclosure	397123000	usd
CY2024Q2	sbra	Preferred Equity Investment Fair Value Disclosure PreferredEquityInvestmentFairValueDisclosure	59201000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	2000000.0	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	23975000	usd
	us-gaap	Net Income Loss NetIncomeLoss	11701000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	231620291	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	231204531	shares
CY2024Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	2130532	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	233750823	shares
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10

Files In Submission

Name	View Source	Status
sbra-20240630_pre.xml	Edgar Link	unprocessable
0001492298-24-000025-index-headers.html	Edgar Link	pending
0001492298-24-000025-index.html	Edgar Link	pending
0001492298-24-000025.txt	Edgar Link	pending
0001492298-24-000025-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sbra-20240630.htm	Edgar Link	pending
sbra-20240630.xsd	Edgar Link	pending
sbra-20240630_def.xml	Edgar Link	unprocessable
sbraex3112024q2.htm	Edgar Link	pending
sbraex3122024q2.htm	Edgar Link	pending
sbraex3212024q2.htm	Edgar Link	pending
sbraex3222024q2.htm	Edgar Link	pending
Show.js	Edgar Link	pending
sbra-20240630_lab.xml	Edgar Link	unprocessable
sbra-20240630_htm.xml	Edgar Link	completed
sbra-20240630_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SBRA
Sabra Health Care REIT, Inc. Stock $sbra

2024 Q3 Form 10-Q Financial Statement

#000149229824000025 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBRA Sabra Health Care REIT, Inc. Stock $sbra

2024 Q3 Form 10-Q Financial Statement

#000149229824000025 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SBRA
Sabra Health Care REIT, Inc. Stock $sbra